A novel congenital dysprothrombinemia leading to defective prothrombin maturation

Valeria Bafunno, Loredana Bury, Giovanni Luca Tiscia, Tiziana Fierro, Giovanni Favuzzi, Rocco Caliandro, Francesco Sessa, Elvira Grandone, Maurizio Margaglione, Paolo Gresele

Research output: Contribution to journalArticle

Abstract

Introduction: Prothrombin deficiency is a very rare disorder caused by mutations in the F2 gene that generate hypoprothrombinemia or dysprothrombinemia and is characterized by bleeding manifestations that can vary from clinically irrelevant to life-threatening. Aim: Here we characterize a patient with a novel missense mutation in F2, c.1090 T/A (p. Val322Glu), that causes severe dysprothrombinemia. Methods: Coagulation assays, prothrombin Western Blotting, FII activation by Ecarin, fibrinogen degradation products quantification and thrombin generation assay were carried out to assess prothrombin expression and function. PCR followed by direct sequencing was carried out to characterize the mutation. In silico analysis for missense variant and molecular modeling were applied to predict the mechanism that leads to dysprothrombinemia. Results and conclusions: The homozygous patient had a markedly prolonged prothrombin time, strongly reduced FII activity (0.82%) but normal antigen levels. In the thrombin generation assay the lag time and the peak height were unmeasurable, suggesting that the Val322Glu mutation results in the inability of the mutant prothrombin to be fully activated to thrombin. In fact, prothrombin activation by ecarin was defective, with a massive accumulation of the meizothrombin intermediate. Molecular modeling and dynamic simulation studies showed that the Val322Glu mutation interferes with protein flexibility at Arg271 and Arg320. This impairs the switch of the protein from zymogen to proteinase, thus preventing the formation of thrombin. Accumulated meizothrombin, however, maintains some fibrinogen-degrading activity, as shown by the formation of FDPs, and this probably explains the patient's mild bleeding phenotype.

Original languageEnglish
Pages (from-to)1135-1141
Number of pages7
JournalThrombosis Research
Volume134
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Prothrombin
Thrombin
Hypoprothrombinemias
Mutation
Fibrinogen
Hemorrhage
Enzyme Precursors
Prothrombin Time
Missense Mutation
Molecular Dynamics Simulation
Computer Simulation
Proteins
Peptide Hydrolases
Western Blotting
Phenotype
Antigens
Polymerase Chain Reaction
Dysprothrombinemia
Genes
meizothrombin

Keywords

  • Dysprothrombinemia
  • Factor II
  • Meizothrombin
  • Molecular modeling
  • Prothrombin activation

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

A novel congenital dysprothrombinemia leading to defective prothrombin maturation. / Bafunno, Valeria; Bury, Loredana; Tiscia, Giovanni Luca; Fierro, Tiziana; Favuzzi, Giovanni; Caliandro, Rocco; Sessa, Francesco; Grandone, Elvira; Margaglione, Maurizio; Gresele, Paolo.

In: Thrombosis Research, Vol. 134, No. 5, 2014, p. 1135-1141.

Research output: Contribution to journalArticle

Bafunno, V, Bury, L, Tiscia, GL, Fierro, T, Favuzzi, G, Caliandro, R, Sessa, F, Grandone, E, Margaglione, M & Gresele, P 2014, 'A novel congenital dysprothrombinemia leading to defective prothrombin maturation', Thrombosis Research, vol. 134, no. 5, pp. 1135-1141. https://doi.org/10.1016/j.thromres.2014.08.028
Bafunno, Valeria ; Bury, Loredana ; Tiscia, Giovanni Luca ; Fierro, Tiziana ; Favuzzi, Giovanni ; Caliandro, Rocco ; Sessa, Francesco ; Grandone, Elvira ; Margaglione, Maurizio ; Gresele, Paolo. / A novel congenital dysprothrombinemia leading to defective prothrombin maturation. In: Thrombosis Research. 2014 ; Vol. 134, No. 5. pp. 1135-1141.
@article{0b25f41694dc4b9f87da0b0ee8b51566,
title = "A novel congenital dysprothrombinemia leading to defective prothrombin maturation",
abstract = "Introduction: Prothrombin deficiency is a very rare disorder caused by mutations in the F2 gene that generate hypoprothrombinemia or dysprothrombinemia and is characterized by bleeding manifestations that can vary from clinically irrelevant to life-threatening. Aim: Here we characterize a patient with a novel missense mutation in F2, c.1090 T/A (p. Val322Glu), that causes severe dysprothrombinemia. Methods: Coagulation assays, prothrombin Western Blotting, FII activation by Ecarin, fibrinogen degradation products quantification and thrombin generation assay were carried out to assess prothrombin expression and function. PCR followed by direct sequencing was carried out to characterize the mutation. In silico analysis for missense variant and molecular modeling were applied to predict the mechanism that leads to dysprothrombinemia. Results and conclusions: The homozygous patient had a markedly prolonged prothrombin time, strongly reduced FII activity (0.82{\%}) but normal antigen levels. In the thrombin generation assay the lag time and the peak height were unmeasurable, suggesting that the Val322Glu mutation results in the inability of the mutant prothrombin to be fully activated to thrombin. In fact, prothrombin activation by ecarin was defective, with a massive accumulation of the meizothrombin intermediate. Molecular modeling and dynamic simulation studies showed that the Val322Glu mutation interferes with protein flexibility at Arg271 and Arg320. This impairs the switch of the protein from zymogen to proteinase, thus preventing the formation of thrombin. Accumulated meizothrombin, however, maintains some fibrinogen-degrading activity, as shown by the formation of FDPs, and this probably explains the patient's mild bleeding phenotype.",
keywords = "Dysprothrombinemia, Factor II, Meizothrombin, Molecular modeling, Prothrombin activation",
author = "Valeria Bafunno and Loredana Bury and Tiscia, {Giovanni Luca} and Tiziana Fierro and Giovanni Favuzzi and Rocco Caliandro and Francesco Sessa and Elvira Grandone and Maurizio Margaglione and Paolo Gresele",
year = "2014",
doi = "10.1016/j.thromres.2014.08.028",
language = "English",
volume = "134",
pages = "1135--1141",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - A novel congenital dysprothrombinemia leading to defective prothrombin maturation

AU - Bafunno, Valeria

AU - Bury, Loredana

AU - Tiscia, Giovanni Luca

AU - Fierro, Tiziana

AU - Favuzzi, Giovanni

AU - Caliandro, Rocco

AU - Sessa, Francesco

AU - Grandone, Elvira

AU - Margaglione, Maurizio

AU - Gresele, Paolo

PY - 2014

Y1 - 2014

N2 - Introduction: Prothrombin deficiency is a very rare disorder caused by mutations in the F2 gene that generate hypoprothrombinemia or dysprothrombinemia and is characterized by bleeding manifestations that can vary from clinically irrelevant to life-threatening. Aim: Here we characterize a patient with a novel missense mutation in F2, c.1090 T/A (p. Val322Glu), that causes severe dysprothrombinemia. Methods: Coagulation assays, prothrombin Western Blotting, FII activation by Ecarin, fibrinogen degradation products quantification and thrombin generation assay were carried out to assess prothrombin expression and function. PCR followed by direct sequencing was carried out to characterize the mutation. In silico analysis for missense variant and molecular modeling were applied to predict the mechanism that leads to dysprothrombinemia. Results and conclusions: The homozygous patient had a markedly prolonged prothrombin time, strongly reduced FII activity (0.82%) but normal antigen levels. In the thrombin generation assay the lag time and the peak height were unmeasurable, suggesting that the Val322Glu mutation results in the inability of the mutant prothrombin to be fully activated to thrombin. In fact, prothrombin activation by ecarin was defective, with a massive accumulation of the meizothrombin intermediate. Molecular modeling and dynamic simulation studies showed that the Val322Glu mutation interferes with protein flexibility at Arg271 and Arg320. This impairs the switch of the protein from zymogen to proteinase, thus preventing the formation of thrombin. Accumulated meizothrombin, however, maintains some fibrinogen-degrading activity, as shown by the formation of FDPs, and this probably explains the patient's mild bleeding phenotype.

AB - Introduction: Prothrombin deficiency is a very rare disorder caused by mutations in the F2 gene that generate hypoprothrombinemia or dysprothrombinemia and is characterized by bleeding manifestations that can vary from clinically irrelevant to life-threatening. Aim: Here we characterize a patient with a novel missense mutation in F2, c.1090 T/A (p. Val322Glu), that causes severe dysprothrombinemia. Methods: Coagulation assays, prothrombin Western Blotting, FII activation by Ecarin, fibrinogen degradation products quantification and thrombin generation assay were carried out to assess prothrombin expression and function. PCR followed by direct sequencing was carried out to characterize the mutation. In silico analysis for missense variant and molecular modeling were applied to predict the mechanism that leads to dysprothrombinemia. Results and conclusions: The homozygous patient had a markedly prolonged prothrombin time, strongly reduced FII activity (0.82%) but normal antigen levels. In the thrombin generation assay the lag time and the peak height were unmeasurable, suggesting that the Val322Glu mutation results in the inability of the mutant prothrombin to be fully activated to thrombin. In fact, prothrombin activation by ecarin was defective, with a massive accumulation of the meizothrombin intermediate. Molecular modeling and dynamic simulation studies showed that the Val322Glu mutation interferes with protein flexibility at Arg271 and Arg320. This impairs the switch of the protein from zymogen to proteinase, thus preventing the formation of thrombin. Accumulated meizothrombin, however, maintains some fibrinogen-degrading activity, as shown by the formation of FDPs, and this probably explains the patient's mild bleeding phenotype.

KW - Dysprothrombinemia

KW - Factor II

KW - Meizothrombin

KW - Molecular modeling

KW - Prothrombin activation

UR - http://www.scopus.com/inward/record.url?scp=84927587023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927587023&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.08.028

DO - 10.1016/j.thromres.2014.08.028

M3 - Article

C2 - 25242243

AN - SCOPUS:84927587023

VL - 134

SP - 1135

EP - 1141

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 5

ER -